Literature DB >> 11948810

Expression of the complement C3a and C5a receptors after permanent focal ischemia: An alternative interpretation.

Scott R Barnum1, Robert S Ames, Peter R Maycox, Sarah J Hadingham, Jackie Meakin, David Harrison, Andrew A Parsons.   

Abstract

The receptors for the complement anaphylatoxins C3a and C5a are expressed by glial cells and neurons in normal and inflamed brain. Previous studies demonstrated modest elevations in mRNA expression of these receptors in a model of focal cerebral ischemia. Using a similar model system for both mice and rats, we report markedly different patterns of anaphylatoxin receptor mRNA expression in cerebral ischemia. C5a receptor expression was dramatically elevated within 3 h after middle cerebral artery occlusion, while C3aR expression was reduced to 25% of control animals. By 24 h post-occlusion, expression of both receptors was higher than at any other time point examined. This increased expression at late time points after occlusion is most likely the result of massive infiltration of leukocytes expressing the receptors. We also observed increased receptor mRNA expression in sham-operated animals, indicating that the procedures used for arterial occlusion affects mechanisms regulating receptor expression. This latter result highlights the importance of including this important control group in ischemic model systems for proper interpretation of changes in gene expression. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11948810     DOI: 10.1002/glia.10069

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  21 in total

Review 1.  Complement-induced impairment of the innate immune system during sepsis.

Authors:  Eric A Albrecht; Peter A Ward
Journal:  Curr Allergy Asthma Rep       Date:  2004-09       Impact factor: 4.806

2.  C5a-induced gene expression in human umbilical vein endothelial cells.

Authors:  Eric A Albrecht; Arul M Chinnaiyan; Sooryanarayana Varambally; Chandan Kumar-Sinha; Terrence R Barrette; J Vidya Sarma; Peter A Ward
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

Review 3.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

Review 4.  The Role of Complement C3a Receptor in Stroke.

Authors:  Saif Ahmad; Kanchan Bhatia; Adam Kindelin; Andrew F Ducruet
Journal:  Neuromolecular Med       Date:  2019-05-17       Impact factor: 3.843

5.  Transcriptional profiling reveals that C5a alters microRNA in brain endothelial cells.

Authors:  Michael T Eadon; Alexander Jacob; Patrick N Cunningham; Richard J Quigg; Joe G N Garcia; Jessy J Alexander
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

6.  Complement-induced Impairment of the Innate Immune System During Sepsis.

Authors:  Eric A Albrecht; Peter A Ward
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

Review 7.  Anaphylatoxins: their role in bacterial infection and inflammation.

Authors:  Pieter-Jan Haas; Jos van Strijp
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

8.  Evaluation of capsular and acapsular strains of S. aureus in an experimental brain abscess model.

Authors:  Nilufer Esen; Gail Wagoner; Napoleon Philips
Journal:  J Neuroimmunol       Date:  2009-11-10       Impact factor: 3.478

9.  C3aR inhibition reduces neurodegeneration in experimental lupus.

Authors:  A Jacob; L Bao; J Brorson; R J Quigg; J J Alexander
Journal:  Lupus       Date:  2009-11-09       Impact factor: 2.911

Review 10.  Phytochemicals in Ischemic Stroke.

Authors:  Joonki Kim; David Yang-Wei Fann; Raymond Chee Seong Seet; Dong-Gyu Jo; Mark P Mattson; Thiruma V Arumugam
Journal:  Neuromolecular Med       Date:  2016-05-18       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.